-transparent.png){kind=logo}
In a double-blind, placebo-controlled study, the central and peripheral hemodynamic effects of 100 mg oral flosequinan and the impact of this drug on neurohormonal activation were noninvasively evaluated in 18 patients with congestive heart failure, after the first administration and after 10 days of treatment. No significant hemodynamic and neurohormonal changes were observed after acute administration. After 10 days, flosequinan produced central and peripheral hemodynamic improvement characterized by an increase in left ventricular circumferential fiber shortening velocity (+12%), a decrease in total systemic resistance (-36%), and an increase in leg blood flow (+37%). No significant changes were observed in heart rate and arterial pressure in patients receiving flosequinan, though a slight increase in heart rate (+17%) was recorded. Despite these favorable hemodynamic effects, flosequinan significantly increased plasma norepinephrine (+38%) and plasma renin activity (+13%) after 10 days of treatment. Thus, the beneficial central and peripheral hemodynamic effects of flosequinan are accompanied by activation of the sympathetic and reninangiotensin systems. This might be related to the unfavorable effects of the drug on survival in patients with heart failure.
R Isnard, and
P Lechat, and
F Pousset, and
A Carayon, and
H Kalotka, and
H Chikr, and
J Salloum, and
D Thomas, and
M Komajda
June 1990,
Cardiovascular drugs and therapy,
R Isnard, and
P Lechat, and
F Pousset, and
A Carayon, and
H Kalotka, and
H Chikr, and
J Salloum, and
D Thomas, and
M Komajda
June 1989,
The American journal of cardiology,
R Isnard, and
P Lechat, and
F Pousset, and
A Carayon, and
H Kalotka, and
H Chikr, and
J Salloum, and
D Thomas, and
M Komajda
March 1995,
Journal of cardiac failure,
R Isnard, and
P Lechat, and
F Pousset, and
A Carayon, and
H Kalotka, and
H Chikr, and
J Salloum, and
D Thomas, and
M Komajda
January 2001,
Congestive heart failure (Greenwich, Conn.),
R Isnard, and
P Lechat, and
F Pousset, and
A Carayon, and
H Kalotka, and
H Chikr, and
J Salloum, and
D Thomas, and
M Komajda
October 1993,
Circulation,
R Isnard, and
P Lechat, and
F Pousset, and
A Carayon, and
H Kalotka, and
H Chikr, and
J Salloum, and
D Thomas, and
M Komajda
November 1991,
Kardiologiia,
R Isnard, and
P Lechat, and
F Pousset, and
A Carayon, and
H Kalotka, and
H Chikr, and
J Salloum, and
D Thomas, and
M Komajda
January 1996,
European journal of clinical pharmacology,
R Isnard, and
P Lechat, and
F Pousset, and
A Carayon, and
H Kalotka, and
H Chikr, and
J Salloum, and
D Thomas, and
M Komajda
October 1992,
Journal of the American College of Cardiology,
R Isnard, and
P Lechat, and
F Pousset, and
A Carayon, and
H Kalotka, and
H Chikr, and
J Salloum, and
D Thomas, and
M Komajda
October 1993,
Journal of the American College of Cardiology,
R Isnard, and
P Lechat, and
F Pousset, and
A Carayon, and
H Kalotka, and
H Chikr, and
J Salloum, and
D Thomas, and
M Komajda
April 2000,
American heart journal,
